GSTK1 suppresses HCC aggravation via L-carnitine metabolism by PGAM5/DRP1 complex-mediated mitochondrial quality control
GSTK1 was shown to be a tumor suppressor via its role in MQC and L-carnitine metabolism. Bexarotene and L-carnitine supplementation may serve as potential therapeutic strategies for HCC treatment.
Authors
- Guangyan Zhangyuan (ORCID: https://orcid.org/0000-0002-6298-8304)
- Baoquan Song (ORCID: https://orcid.org/0000-0002-6046-8209)
- Beicheng Sun (ORCID: https://orcid.org/0000-0002-8657-7024)
- Haitian Zhang (ORCID: https://orcid.org/0000-0002-1122-8647)
- Wenjie Zhang (ORCID: https://orcid.org/0000-0001-6970-3909)
- Fei Wang (ORCID: https://orcid.org/0000-0002-5670-1944)
- Kangpeng Jin (ORCID: https://orcid.org/0000-0003-0290-4276)
- Jinyao Zhang (ORCID: https://orcid.org/0000-0001-5657-9013)
- Weiwei Yu (ORCID: https://orcid.org/0000-0002-6009-5844)
- Ke Ding (ORCID: https://orcid.org/0000-0002-1107-4131)
- Jianbo He (ORCID: https://orcid.org/0000-0002-0623-9763)
- Yuze Shi (ORCID: https://orcid.org/0000-0002-5233-434X)
Institutions
- Anhui University (CN)
- Shanghai Jiao Tong University (CN)
- Anhui Medical University (CN)
- Ruijin Hospital (CN)
- Nanjing Drum Tower Hospital (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1186/s13046-025-03580-8
- Primary Topic
- Folate and B Vitamins Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00